cat no | io1033, io1034
ioMicroglia APOE 4/3 are opti-ox deterministically programmed microglia carrying a genetically engineered heterozygous C112R mutation in the APOE gene, converting the wild-type APOE3 allele to APOE4, encoding the apolipoprotein E4. The APOE4 allele is the strongest genetic risk factor for late-onset Alzheimer's disease (AD).
These cells offer a functional, rapidly maturing, and disease relevant system to study the role of APOE4 in late-onset AD, alongside a genetically matched wild-type control.
Confidently investigate your phenotype of interest across multiple clones with our disease model clone panel. Detailed characterisation data (below) and bulk RNA sequencing data (upon request) help you select specific clones if required.
per vial
A maximum number of 20 vials applies. If you would like to order more than 20 vials, please contact us at orders@bit.bio.
Making True Comparisons
Pair the ioDisease Model Cells with the genetically matched wild-type ioMicroglia to directly investigate the effect of APOE4 on late-onset AD.
Quick
Rapidly maturing cells that are ready to use within 10 days post-revival, in mono- and co-cultures.
Functional
Disease model cells display key phagocytic and cytokine secretion functions.
ioMicroglia APOE 4/3 are delivered in a cryopreserved format and are programmed to rapidly mature upon revival in the recommended media. The protocol for the generation of these cells is a three-phase process: an Induction phase that is carried out at bit.bio, Phase 1: Stabilisation for 24 hours, Phase 2: Maturation for a further 9 days, Phase 3: the Maintenance phase. Cells are ready to use from day 10.
Disease model cells express key microglia markers comparably to the genetically matched wild-type control
Immunofluorescent staining on day 10 post-revival demonstrates similar homogenous expression of microglia markers P2RY12 and IBA1 and ramified morphology in both disease model clones compared to the genetically matched wild-type (WT) control. 100X magnification.
Disease model cells show expected ramified morphology by day 10
Both disease model clones mature rapidly and key ramified morphology can be identified by day 4 and continues through to day 10, similarly to the WT control. Day 1 to 10 post-thawing; 100x magnification.
Disease model cells display reduced secretion of pro-inflammatory cytokines, IL-12p70, IL-1β, and TNF⍺, upon activation compared to the genetically matched wild-type control
Cytokine secretion was analysed at day 10 post-revival after stimulation with LPS 100 ng/ml and IFNɣ 20 ng/ml for 24 hours. This revealed that both disease model clones secrete the pro-inflammatory cytokines, IL-12p70, IL-1β, and TNF⍺ at a lower-level than the WT control whereas IL-6 and IL-8, appear to be secreted at a similar level to the WT control. Clone CL53 secretes the anti-inflammatory IL-10 at a lower level whereas clone CL80 secretes this cytokine at a similar level to the WT control. Supernatants were harvested and analysed using MSD V-plex Proinflammatory Kit. Three technical replicates were performed per experiment.
Starting material
Human iPSC line
Seeding compatibility
6, 12, 24, 96 & 384 well plates
Shipping info
Dry ice
Donor
Caucasian adult male (skin fibroblast)
Vial size
Small: >1.5 x 10⁶ viable cells
Quality control
Sterility, protein expression (ICC), functional phagocytosis and cytokine secretion assays
Differentiation method
opti-ox deterministic cell programming
Recommended seeding density
37,000 to 39,500 cells/cm²
User storage
LN2 or -150°C
Format
Cryopreserved cells
Product use
ioCells are for research use only
Genetic modification
Heterozygous C112R mutation in the APOE gene
Applications
Alzheimer's disease modelling
Drug discovery and development
Neuroinflammation modelling
Phagocytosis assays
cytokine response assays
Co-culture studies
Available clones
io1033S: ioMicroglia APOE 4/3 C112R/WT (CL53)
io1034S: ioMicroglia APOE 4/3 C112R/WT (CL80)
Elise Malavasi, PhD
Principal Scientist
Concept Life Sciences
bit.bio | Medicines Discovery Catapult
2024
In this GEN webinar, hear from our distinguished expert, Dr Matthias Pawlowski, and learn about the emerging role of microglia in the pathogenesis of Alzheimer’s disease and their potential as a therapeutic target to treat this disease effectively.
Consistent. Defined. Scalable.